Colorectal liver metastases (CRLM) affect over 50 % of all patients with colorectal cancer, which is the second leading cause of cancer in the western world. Resection of CRLM may provide cure and improves survival over chemotherapy alone. However, resectability of CLRM has to be decided in multidisciplinary tumor boards and is based on oncological factors, technical factors and patient factors.

The advances of chemotherapy lead to the abolition of contraindications to resection in favor of technical resectability, but somatic mutations and molecular subtyping may improve selection of patients for resection in the future. Technical factors center around anatomy of the lesions, volume of the remnant liver and quality of the liver parenchymal. Multiple strategies have been developed to overcome volume limitations and they are reviewed here. The least investigated topic is how to select the right patients among an elderly and frail patient population for the large variety of technical options specifically for bi-lobar CRLM to keep 90-day mortality as low as possible.

The review is an overview over the current state-of-the art and a systematic guide to the topic of resectability of CRLM for both clinicians and patients.

结直肠肝转移 (CRLM) 影响超过 50% 的结直肠癌患者，这是西方世界癌症的第二大原因。与单纯化疗相比，切除 CRLM 可以治愈并提高生存率。然而，CLRM 的可切除性必须在多学科肿瘤委员会中决定，并且基于肿瘤学因素、技术因素和患者因素。

化疗的进步导致切除禁忌症的取消，有利于技术可切除性，但体细胞突变和分子亚型可能会改善未来患者的切除选择。技术因素集中在病变的解剖结构、残肝体积和肝实质质量。已经开发了多种策略来克服体积限制，并在此处对其进行了回顾。研究最少的话题是如何在老年人和体弱的患者群体中为各种专门针对双叶 CRLM 的技术选择选择合适的患者，以尽可能降低 90 天死亡率。

该综述是对当前最先进技术的概述，也是对临床医生和患者的 CRLM 可切除性主题的系统指南。